bibliographicCitation |
Basit S, Ashraf Z, Lee K, Latif M. First macrocyclic 3 rd -generation ALK inhibitor for treatment of ALK/ROS1 cancer: Clinical and designing strategy update of lorlatinib. European Journal of Medicinal Chemistry. 2017 Jul;134():348–56. doi: 10.1016/j.ejmech.2017.04.032. |